US-based biotechnology company Trovagene has chosen global contract research organisation (CRO) PRA Health Sciences to carry out its Phase lb/ll clinical trial of PCM-075, a polo-like kinase 1 (PLK1) inhibitor, to treat patients with acute myeloid leukaemia (AML).

As part of the latest arrangement, PRA will help Trovagene in clinical site recruitment, clinical operations and regulatory proceedings for the development of PCM-075 in AML.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Trovagene has already filed an investigational new drug (IND) application and protocol for PCM-075 to the Food and Drug Administration (FDA).

Once approved, the company is planning to commence the Phase lb/ll study that will assess the safety, tolerability, dosage and scheduling, as well as preliminary efficacy of PCM-075 in patients with AML.

"We look forward to generating clinical data that we believe will assess the safety, tolerability, and anti-leukaemic activity of PCM-075 in a haematological malignancy."

Trovagene CEO Bill Welch said: “We look forward to generating clinical data that we believe will assess the safety, tolerability, and anti-leukaemic activity of PCM-075 in a haematological malignancy.”

The company’s PCM-075 is an adenosine triphosphate (ATP) competitive inhibitor of the serine / threonine polo-like-kinase 1 (PLK 1) enzyme, which is over-expressed in several different hematologic malignancies, as well as solid tumours such as breast, prostate, ovarian, lung, gastric and colon cancers.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The PLK1is orally bioavailable and has already been explored in an initial, open-label, dose-escalation safety Phase l study in patients with advanced metastatic solid tumour cancers.

PCM-075 demonstrated an acceptable safety profile, as well as anti-tumour activity in the study.

Last month, Trovagene signed a supplier agreement with Italy’s Nerviano Medical Sciences subsidiary NerPharMato manufacture drug product for PCM-075.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact